Skip to main content

Table 5 Summary of TEAEs (safety analysis set)

From: Pharmacokinetics and bioequivalence evaluation of two oral formulations of cotrimoxazole tablets in healthy Chinese volunteers under fasting conditions

Most common TEAEs

Test (N = 26)

Reference(N = 26)

Case(N)

Number of cases (%)

Case(N)

Number of cases (%)

Infectious and invasive diseases, N (%)

1

1(3.8)

0

0(0.0)

Fever Blisters

1

1(3.8)

0

0(0.0)

Laboratory findings

0

0(0.0)

1

1(3.8)

Hematemesis

0

0(0.0)

1

1(3.8)

Nervous system disorders

1

1(3.8)

0

0(0.0)

Dizziness

1

1(3.8)

0

0(0.0)

Diseases of the respiratory system, chest, and mediastinum

0

0(0.0)

1

1(3.8)

 Hiccup

0

0(0.0)

1

1(3.8)

Kidney and urinary diseases

0

0(0.0)

1

1(3.8)

 Oliguria

0

0(0.0)

1

1(3.8)

Gastrointestinal diseases

0

0(0.0)

1

1(3.8)

Abdominal Discomfort

0

0(0.0)

1

1(3.8)

Eye organ diseases

0

0(0.0)

1

1(3.8)

Asthenopia

0

0(0.0)

1

1(3.8)

  1. TEAEs, treatment-emergent adverse event